Company intelligence / Profile preview

Jeito Capital

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Jeito Capital has built a diversified global biopharma investment portfolio spanning cell therapies, gene therapies, antibodies, ADCs, radiopharmaceuticals and more. Its investments support companies at various stages of development—from preclinical through Phase III—with several notable exits including the acquisition of HI-Bio by Biogen for up to $1.8 billion in July 2024. The fund emphasizes patient benefit-driven innovation with a strong presence in Europe and the US.

Therapeutic areas: PulmonologyCardiovascularOphthalmologyImmunologyOtherOncologyNeurology
Modalities: Cell therapyGene therapyAntibodySmall moleculeAntibody-drug conjugateRadiopharmaceuticalProteinPeptides
Industry: Investors

Partnerships

ARCH Venture PartnersOmega FundsEQTFountain Healthcare PartnersLumira Ventures

Beyond the preview

Go deeper on Jeito Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jeito Capital.

Explore the full profile